Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has returned. But this was predictable, yes? After all, the world — such as it is — keeps spinning, no matter how hard we try to slow it down. So perhaps giving it a nudge in a better direction with a cup or three of stimulation is in order. Our choice today is bourbon pecan. Please feel free to join us. Meanwhile, here is the latest list of interesting items for you to peruse as you start your own journey. We hope your day is productive and meaningful. And of course, do keep in touch. …
Amgen is in a heated fight with the U.S. Internal Revenue Service over its international tax strategy and $10.7 billion in back taxes and penalties that the agency says it is owed, The Wall Street Journal writes. The IRS says that Amgen underreported its taxable income by nearly $24 billion from 2010 to 2015 by inappropriately attributing what the agency says should have been U.S. profits to a Puerto Rico subsidiary that oversees manufacturing of the company’s drugs. The dispute with the IRS is the latest example of heightened government scrutiny of the international tax practices of pharmaceutical, technology, and other companies.
Beyond donations from a few high-income countries that have stockpiled the monkeypox vaccine, primarily the U.S., it remains unclear how the world could meet rising demand for a vaccine following the declaration of a global health emergency, Health Policy Watch explains. Only 16.4 million doses of the monkeypox vaccine made by Bavarian Nordic are available worldwide, and its European manufacturing plant is shuttered until the fall of 2022. The U.S. government will be in possession of, or contracted to receive, the overwhelming majority of doses due to be delivered in 2022 — roughly adding up to about 14.4 million doses.
Create a display name to comment
This name will appear with your comment